EBOS Group Limited AI Stock Analysis
Want to see NZ:EBO full AI Analyst Report?
EBOS Group Limited (EBO) AI Stock Analysis
EBOS Group Limited
(NZX:EBO)
The score is held back primarily by weaker financial consistency (FY2026 revenue and margin deterioration) and bearish technical momentum (downtrend across key moving averages, negative MACD). Offsetting factors include a supportive valuation profile (moderate P/E and high dividend yield) and a solid earnings-call outlook with FY27 EBITDA growth guidance and improving free-cash-flow expectations from lower CapEx, despite acknowledged headwinds.
EBOS Group Limited (EBO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- NZD 3.74B
- Dividend Yield
- 5.67%
- Average Volume (3M)
- 186.56K
- Price to Earnings (P/E)
- 16.7
- Beta (1Y)
- 0.90
- Revenue Growth
- 16.36%
- EPS Growth
- 5.52%
- Country
- NZ
- Employees
- 5,364
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
EBOS Group Limited Business Overview & Revenue Model
Company Description
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The comp...
How the Company Makes Money
EBOS primarily makes money by acting as a large-scale wholesaler and distributor between manufacturers (pharmaceutical, medical device/consumables, and animal health suppliers) and end customers (notably community pharmacies, hospitals, healthcare pr...
EBOS Group Limited Earnings Call Summary
The call communicated solid top‑line growth, completion of a major A$360m infrastructure program that materially reduces future capital needs, meaningful momentum in higher-growth divisions (Animal Care, Medical Technology, Retail Pharmacy Brands) and a disciplined M&A and capital allocation approach. Temporary headwinds were acknowledged — notably FX translation, fuel costs, margin pressure and a known NZ contract roll-off — but management framed these as manageable or transitory and backed guidance that excludes further acquisitions. Balance sheet metrics, free cash flow generation and a maintained dividend were highlighted as strengths. Overall the positives (portfolio re‑positioning, completed investment cycle, strong divisional growth and capital flexibility) outweigh the measurable but contained lowlights.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
EBOS guided FY27 underlying EBITDA of A$635–655 million (midpoint ~A$645m), implying mid‑single‑digit EBITDA growth and explicitly excluding any new acquisitions; CapEx is expected to normalise to ~A$100m (down from A$145m in FY26), supporting stronger free cash flow after FY26 reported free cash flow of A$204m and facilitating ~A$150m of additional bolt‑on M&A capacity within a leverage ceiling of 2.3x (FY26 leverage 2.1x, target range 1.7–2.3x) and with A$726m undrawn committed facilities and WA debt maturity >3 years. Management also flagged a targeted 30% productivity uplift at Kemps Creek by end FY27, stable cash conversion days (~20) and only A$7m NWC growth on 10% revenue growth, while noting depreciation and financing costs will be elevated as recent investments are annualised and the final dividend was maintained at A$0.615 per share.
EBOS Group Limited Financial Statement Overview
Summary
Financials look generally stable but are clouded by FY2026 volatility: a sharp revenue contraction and notable margin compression reduce confidence in earnings quality. Offsetting this, leverage appears manageable and free cash flow remains positive, indicating underlying resilience.
Income Statement
58NeutralBalance Sheet
64PositiveCash Flow
62Positive| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.17B | 12.84B | 12.20B | 13.15B | 12.25B | 10.77B |
| Gross Profit | 933.71M | 910.40M | 1.63B | 1.63B | 1.56B | 1.25B |
| EBITDA | 544.98M | 531.22M | 535.23M | 593.97M | 575.21M | 401.44M |
| Net Income | 219.64M | 214.33M | 213.89M | 270.67M | 253.57M | 203.26M |
Balance Sheet | ||||||
| Total Assets | 7.83B | 7.83B | 7.24B | 6.72B | 6.44B | 6.28B |
| Cash, Cash Equivalents and Short-Term Investments | 239.29M | 239.29M | 183.19M | 249.74M | 212.05M | 518.99M |
| Total Debt | 1.90B | 1.90B | 1.61B | 1.64B | 1.28B | 1.65B |
| Total Liabilities | 5.12B | 5.12B | 4.53B | 4.31B | 4.14B | 4.13B |
| Stockholders Equity | 2.75B | 2.75B | 2.72B | 2.45B | 2.44B | 2.27B |
Cash Flow | ||||||
| Free Cash Flow | 213.26M | 207.07M | 365.99M | 262.89M | 293.26M | 159.62M |
| Operating Cash Flow | 345.31M | 332.10M | 416.08M | 347.11M | 391.68M | 249.54M |
| Investing Cash Flow | -274.43M | -258.79M | -366.72M | -376.90M | -154.39M | -1.40B |
| Financing Cash Flow | -4.03M | -11.74M | -84.41M | 34.22M | -547.56M | 1.51B |
EBOS Group Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:EBO, the sentiment is Positive. The current price of 21.73 is above the 20-day moving average (MA) of 21.26, above the 50-day MA of 20.31, and above the 200-day MA of 20.99, indicating a bullish trend. The MACD of 0.45 indicates Negative momentum. The RSI at 57.30 is Neutral, neither overbought nor oversold. The STOCH value of 60.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NZ:EBO.
EBOS Group Limited Peers Comparison
Overall Rating
NZ:FPH80Outperform
NZ:EBO60Neutral
NZ:RYM56Neutral
NZ:AFT54Neutral
NZ:PEB45Neutral
NZ:TRU37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | NZD 29.03B | 61.65 | 22.84% | 1.24% | 15.59% | 23.94% | |
| 60Neutral | NZD 4.54B | 16.73 | 7.99% | 5.67% | 16.36% | 5.52% | |
| 56Neutral | NZD 1.91B | -11.19 | -4.17% | ― | 11.86% | 72.99% | |
| 54Neutral | NZD 485.57M | 32.39 | 14.07% | 0.64% | 22.44% | 23.14% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | NZD 341.52M | -6.92 | -190.54% | ― | -47.36% | -3.79% | |
| 37Underperform | NZD 8.38M | -2.58 | -75.57% | ― | 42.20% | 23.68% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NZ:EBO | EBOS Group Limited | 21.73 | -5.67 | -20.68% | |
| NZ:FPH | Fisher & Paykel Healthcare Corporation Limited | 49.35 | 12.63 | 34.41% | |
| NZ:PEB | Pacific Edge Limited | 0.28 | 0.09 | 51.93% | |
| NZ:RYM | Ryman Healthcare | 1.88 | -1.01 | -34.93% | |
| NZ:TRU | TruScreen Group Ltd. | 0.01 | -0.01 | -41.18% | |
| NZ:AFT | AFT Pharmaceuticals Ltd. | 4.63 | 0.97 | 26.47% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 05, 2026
